‹ ›
MYP_062242
← PREVIOUS NEXT → BACK
Basic Information
ENF (T-20)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Anti-Pneumovirus ▸ Anti-RSV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
36 amino acids
C202H298N50O64
Standard
Sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
Physicochemical Analysis
4450.82 Da
4.30
-5.14
-5.41
-0.1427
-0.88
0.46
-0.05
62.65
89.44
0.1389
17990.00
17990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1894.02
-14.96
63.0
60.0
150.0
316.0
9.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0203015 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
HIV-1 LAI in peripheral blood mononuclear cells
0.24 μM
EC50
PaperDesign of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity PMID18197613 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/18197613/
RECORD: Rec_0209735 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
IIIB virus virus
0.006 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 31680 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0212433 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098 | CEM4 cells
0.01123 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0212919 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
Enfuvirtide
9606
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
MT-4
Qualitative inhibition
PaperInhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. PMID17210123 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17210123/
RECORD: Rec_0213138 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR2 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV Anti-RSV Fusion inhibitor
HIV
PaperMode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage; Patent: Human respiratory syncytial virus peptides with antifusogenic and antiviral activities PMID11027678 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/11027678/ PatentUS 6228983 B1
FIRST PREV 1 ... 5 6 7 8 9 ... 14 NEXT LAST
Showing 5 records on this page · Page 7 of 14